Translational considerations for cancer nanomedicine.
There are many important considerations during preclinical development of cancer nanomedicines, including: 1) unique aspects of animal study design; 2) the difficulties in evaluating biological potency, especially for complex formulations; 3) the importance of analytical methods that can determine platform stability in vivo, and differentiate bound and free active pharmaceutical ingredient (API) in biological matrices; and 4) the appropriateness of current dose scaling techniques for estimation of clinical first-in-man dose from preclinical data. Biologics share many commonalities with nanotechnology products with regard to complexity and biological attributes, and can, in some cases, provide context for dealing with these preclinical issues. In other instances, such as the case of in vivo stability analysis, new approaches are required. This paper will discuss the significance of these preclinical issues, and present examples of current methods and best practices for addressing them. Where possible, these recommendations are justified using the existing regulatory guidance literature.
Stern
Stephan T
ST
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, PO Box B, Frederick, MD 21702, USA. sternstephan@mail.nih.gov
Hall
Jennifer B
JB
Yu
Lee L
LL
Wood
Laura J
LJ
Paciotti
Giulio F
GF
Tamarkin
Lawrence
L
Long
Stephen E
SE
McNeil
Scott E
SE
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D050997:Nanomedicine; D049329:Nanostructures / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley
D000970:Antineoplastic Agents
Nanomedicine. 2006 Jun;2(2):127-36
17292125
Bioconjug Chem. 2010 Jan;21(1):93-101
19958018
J Pharm Sci. 2003 Oct;92(10):1990-2007
14502539
Risk Anal. 1992 Jun;12(2):301-10
1502377
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):213-8
18191625
Biochim Biophys Acta. 1992 Feb 17;1104(1):95-101
1550858
Biomaterials. 2008 Apr;29(12):1912-9
18242692
Mol Cancer Ther. 2007 Nov;6(11):3019-27
18025286
Toxicol Appl Pharmacol. 2008 May 15;229(1):121-34
18355886
Acta Biomater. 2010 Feb;6(2):502-10
19596094
Int J Toxicol. 2008 Sep-Oct;27(5):359-67
19037806
J Pharm Sci. 2009 Oct;98(10):3850-61
19177515
J Intern Med. 2010 Jan;267(1):89-105
20059646
Clin Pharmacokinet. 1994 Oct;27(4):256-69
7834963
Cancer Chemother Pharmacol. 1998;41(3):173-85
9443633
Nanotechnology. 2009 Mar 25;20(12):125701
19420478
Bioconjug Chem. 2005 Jan-Feb;16(1):122-30
15656583
Sci Total Environ. 2008 Dec 15;407(1):165-77
18952258
J Control Release. 2009 Oct 1;139(1):81-4
19538994
J Pharm Sci. 2004 Jan;93(1):177-85
14648647
Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):193-9
15733214
Am J Anat. 1988 Mar;181(3):217-34
3284325
J Leukoc Biol. 2005 Sep;78(3):585-94
15923216
Clin Cancer Res. 2007 Dec 1;13(23):7217-23
18056203
Risk Anal. 1988 Mar;8(1):119-25
3375501
Br J Cancer. 2001 May 18;84(10):1424-31
11355958
Anticancer Drugs. 2008 Feb;19(2):143-9
18176110
Cancer Chemother Rep. 1966 May;50(4):219-44
4957125
Am J Physiol. 1999 Jan;276(1):L146-54
9887067
J Control Release. 1999 Aug 27;61(1-2):93-106
10469906
Adv Drug Deliv Rev. 2009 Jun 21;61(6):422-7
19389437
Drug Metab Dispos. 2008 Aug;36(8):1709-15
18490436
Drug Metab Dispos. 2006 Jun;34(6):971-5
16531476
J Hazard Mater. 2009 Feb 15;162(1):57-65
18554790
Biochim Biophys Acta. 1999 Dec 10;1489(1):69-84
10806998
Am J Ther. 2001 Mar-Apr;8(2):109-16
11304664
J Pharm Biomed Anal. 1989;7(2):189-97
2488620
Mol Pharm. 2008 Jul-Aug;5(4):487-95
18510338
Cancer Res. 1995 Oct 15;55(20):4611-22
7553638
J Biomed Opt. 2008 Jan-Feb;13(1):014024
18315382
J Drug Target. 1994;2(1):61-77
8069585
Pharm Res. 1995 Jan;12(1):85-7
7724492
Int Immunopharmacol. 2008 Mar;8(3):401-13
18279794
Toxicol Lett. 2009 Sep 28;189(3):177-83
19397964
Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8
12507764
Curr Pharm Des. 2009;15(9):988-1007
19275663